No incidence of nephrogenic systemic fibrosis after gadobenate dimeglumine administration in patients undergoing dialysis or those with severe chronic kidney disease

Diego R. Martin, Bobby Kalb, Ankush Mittal, Khalil Salman, Srinivasan Vedantham, Pardeep Mittal

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To determine the incidence of nephrogenic systemic fibrosis (NSF) in patients with severe chronic kidney disease (CKD) who underwent a uniform protocol for contrast material-enhanced magnetic resonance (MR) imaging with a gadolinium-based contrast agent (GBCA). Materials and Methods: This retrospective, single-center, institutional review board-approved, HIPAA-compliant study included 3819 patients with severe (stage 4 or 5) CKD who underwent gadobenate dimeglumine-enhanced MR imaging as part of a preoperative evaluation for potential renal transplantation from January 2008 to February 2014. After undergoing contrast-enhanced MR imaging, patients were assessed for NSF by means of clinical follow-up, including a full integumentary examination, with a minimum of 6 months between administration of the GBCA and clinical skin examination. Suspicious skin lesions were sampled with deep punch biopsy, and results of pathologic examination were reviewed and categorized. In addition, a search of the institution's pathology database during the time of the study was performed to identify any additional patients with NSF. The proportion of subjects who developed NSF after the administration of gadobenate dimeglumine was calculated, and Clopper-Pearson 95% confidence intervals were determined by using binomial proportions. Results: The average length of follow-up for the patient population was 501 days (range, 186-2121 days). A total of 219 biopsies were performed, and none of the 3819 patients developed NSF after administration of gadobenate dimeglumine, resulting in a proportion of zero; the exact upper bound of 95% confidence interval was 0.000965 (0.0965%). Conclusion: None of the 3819 patients with severe CKD developed NSF after undergoing gadobenate dimeglumine-enhanced MR imaging, which suggests that this GBCA may be safely administered in patients with severe CKD, with an immeasurable risk for the subsequent development of NSF.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalRadiology
Volume286
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Nephrogenic Fibrosing Dermopathy
Chronic Renal Insufficiency
Dialysis
Incidence
Contrast Media
Gadolinium
Magnetic Resonance Imaging
Confidence Intervals
Health Insurance Portability and Accountability Act
Biopsy
Skin
Time and Motion Studies
gadobenic acid
Research Ethics Committees
Kidney Transplantation
Databases
Pathology

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

No incidence of nephrogenic systemic fibrosis after gadobenate dimeglumine administration in patients undergoing dialysis or those with severe chronic kidney disease. / Martin, Diego R.; Kalb, Bobby; Mittal, Ankush; Salman, Khalil; Vedantham, Srinivasan; Mittal, Pardeep.

In: Radiology, Vol. 286, No. 1, 01.01.2018, p. 113-119.

Research output: Contribution to journalArticle

Martin, Diego R. ; Kalb, Bobby ; Mittal, Ankush ; Salman, Khalil ; Vedantham, Srinivasan ; Mittal, Pardeep. / No incidence of nephrogenic systemic fibrosis after gadobenate dimeglumine administration in patients undergoing dialysis or those with severe chronic kidney disease. In: Radiology. 2018 ; Vol. 286, No. 1. pp. 113-119.
@article{372706133a2742728c646b9bd8496f9e,
title = "No incidence of nephrogenic systemic fibrosis after gadobenate dimeglumine administration in patients undergoing dialysis or those with severe chronic kidney disease",
abstract = "Purpose: To determine the incidence of nephrogenic systemic fibrosis (NSF) in patients with severe chronic kidney disease (CKD) who underwent a uniform protocol for contrast material-enhanced magnetic resonance (MR) imaging with a gadolinium-based contrast agent (GBCA). Materials and Methods: This retrospective, single-center, institutional review board-approved, HIPAA-compliant study included 3819 patients with severe (stage 4 or 5) CKD who underwent gadobenate dimeglumine-enhanced MR imaging as part of a preoperative evaluation for potential renal transplantation from January 2008 to February 2014. After undergoing contrast-enhanced MR imaging, patients were assessed for NSF by means of clinical follow-up, including a full integumentary examination, with a minimum of 6 months between administration of the GBCA and clinical skin examination. Suspicious skin lesions were sampled with deep punch biopsy, and results of pathologic examination were reviewed and categorized. In addition, a search of the institution's pathology database during the time of the study was performed to identify any additional patients with NSF. The proportion of subjects who developed NSF after the administration of gadobenate dimeglumine was calculated, and Clopper-Pearson 95{\%} confidence intervals were determined by using binomial proportions. Results: The average length of follow-up for the patient population was 501 days (range, 186-2121 days). A total of 219 biopsies were performed, and none of the 3819 patients developed NSF after administration of gadobenate dimeglumine, resulting in a proportion of zero; the exact upper bound of 95{\%} confidence interval was 0.000965 (0.0965{\%}). Conclusion: None of the 3819 patients with severe CKD developed NSF after undergoing gadobenate dimeglumine-enhanced MR imaging, which suggests that this GBCA may be safely administered in patients with severe CKD, with an immeasurable risk for the subsequent development of NSF.",
author = "Martin, {Diego R.} and Bobby Kalb and Ankush Mittal and Khalil Salman and Srinivasan Vedantham and Pardeep Mittal",
year = "2018",
month = "1",
day = "1",
doi = "10.1148/radiol.2017170102",
language = "English (US)",
volume = "286",
pages = "113--119",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - No incidence of nephrogenic systemic fibrosis after gadobenate dimeglumine administration in patients undergoing dialysis or those with severe chronic kidney disease

AU - Martin, Diego R.

AU - Kalb, Bobby

AU - Mittal, Ankush

AU - Salman, Khalil

AU - Vedantham, Srinivasan

AU - Mittal, Pardeep

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To determine the incidence of nephrogenic systemic fibrosis (NSF) in patients with severe chronic kidney disease (CKD) who underwent a uniform protocol for contrast material-enhanced magnetic resonance (MR) imaging with a gadolinium-based contrast agent (GBCA). Materials and Methods: This retrospective, single-center, institutional review board-approved, HIPAA-compliant study included 3819 patients with severe (stage 4 or 5) CKD who underwent gadobenate dimeglumine-enhanced MR imaging as part of a preoperative evaluation for potential renal transplantation from January 2008 to February 2014. After undergoing contrast-enhanced MR imaging, patients were assessed for NSF by means of clinical follow-up, including a full integumentary examination, with a minimum of 6 months between administration of the GBCA and clinical skin examination. Suspicious skin lesions were sampled with deep punch biopsy, and results of pathologic examination were reviewed and categorized. In addition, a search of the institution's pathology database during the time of the study was performed to identify any additional patients with NSF. The proportion of subjects who developed NSF after the administration of gadobenate dimeglumine was calculated, and Clopper-Pearson 95% confidence intervals were determined by using binomial proportions. Results: The average length of follow-up for the patient population was 501 days (range, 186-2121 days). A total of 219 biopsies were performed, and none of the 3819 patients developed NSF after administration of gadobenate dimeglumine, resulting in a proportion of zero; the exact upper bound of 95% confidence interval was 0.000965 (0.0965%). Conclusion: None of the 3819 patients with severe CKD developed NSF after undergoing gadobenate dimeglumine-enhanced MR imaging, which suggests that this GBCA may be safely administered in patients with severe CKD, with an immeasurable risk for the subsequent development of NSF.

AB - Purpose: To determine the incidence of nephrogenic systemic fibrosis (NSF) in patients with severe chronic kidney disease (CKD) who underwent a uniform protocol for contrast material-enhanced magnetic resonance (MR) imaging with a gadolinium-based contrast agent (GBCA). Materials and Methods: This retrospective, single-center, institutional review board-approved, HIPAA-compliant study included 3819 patients with severe (stage 4 or 5) CKD who underwent gadobenate dimeglumine-enhanced MR imaging as part of a preoperative evaluation for potential renal transplantation from January 2008 to February 2014. After undergoing contrast-enhanced MR imaging, patients were assessed for NSF by means of clinical follow-up, including a full integumentary examination, with a minimum of 6 months between administration of the GBCA and clinical skin examination. Suspicious skin lesions were sampled with deep punch biopsy, and results of pathologic examination were reviewed and categorized. In addition, a search of the institution's pathology database during the time of the study was performed to identify any additional patients with NSF. The proportion of subjects who developed NSF after the administration of gadobenate dimeglumine was calculated, and Clopper-Pearson 95% confidence intervals were determined by using binomial proportions. Results: The average length of follow-up for the patient population was 501 days (range, 186-2121 days). A total of 219 biopsies were performed, and none of the 3819 patients developed NSF after administration of gadobenate dimeglumine, resulting in a proportion of zero; the exact upper bound of 95% confidence interval was 0.000965 (0.0965%). Conclusion: None of the 3819 patients with severe CKD developed NSF after undergoing gadobenate dimeglumine-enhanced MR imaging, which suggests that this GBCA may be safely administered in patients with severe CKD, with an immeasurable risk for the subsequent development of NSF.

UR - http://www.scopus.com/inward/record.url?scp=85038970148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038970148&partnerID=8YFLogxK

U2 - 10.1148/radiol.2017170102

DO - 10.1148/radiol.2017170102

M3 - Article

C2 - 28731375

AN - SCOPUS:85038970148

VL - 286

SP - 113

EP - 119

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -